| Jul 22 |
Ionis announces positive detailed results from the HALOS Study of ION582 in people with Angelman syndrome
|
| Jul 19 |
Ionis (IONS) Completes Enrolment for Rare Disease Drug Study
|
| Jul 19 |
Ionis to hold second quarter 2024 financial results webcast
|
| Jul 19 |
Ionis completes subject enrolment in Alexander disease treatment trial
|
| Jul 18 |
Ionis completes enrollment in pivotal trial evaluating zilganersen in people living with Alexander disease
|
| Jul 12 |
Silence Therapeutics (SLN) Moves 5.8% Higher: Will This Strength Last?
|
| Jul 8 |
Ionis announces webcast to report HALOS study results for ION582 in Angelman syndrome
|
| Jun 26 |
FDA Accepts Ionis' (IONS) NDA for Rare Disease Drug Olezarsen
|
| Jun 25 |
Ionis gains as anti-lipid therapy undergoes FDA priority review
|
| Jun 25 |
Ionis announces olezarsen FCS New Drug Application accepted for Priority Review and enrollment in Phase 3 sHTG program completed
|
